Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CDC

- PMLiVE

AstraZeneca’s rare disease unit to acquire Pfizer’s early-stage gene therapies for $1bn

The transaction could potentially see staff associated with the portfolio move to Alexion

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody receives FDA approval for use in infants

Beyfortus is the now first preventive option approved in the US to protect a broad infant population

- PMLiVE

Sanofi and Scribe announce in vivo genetic therapy partnership worth over $1.2bn

The agreement expands the companies’ existing collaboration focused on ex vivo editing

- PMLiVE

GSK’s RSV vaccine Arexvy granted approval by MHRA for older adults

RSV infections in older adults account for about 14,000 hospitalisations each year in the UK

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

AstraZeneca’s phase 3 liver cancer study shows continued survival benefit

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

Sanofi’s amlitelimab shows promise in phase 2b atopic dermatitis trial

The inflammatory skin disease affects an estimated 16.5 million adults in the US

- PMLiVE

Sanofi and Sobi’s haemophilia A treatment shows effective bleed protection in children

Current factor VIII therapies usually require patients to receive treatment multiple times a week

- PMLiVE

GSK’s RSV vaccine shows long-term efficacy in late-stage older adults study

Arexvy was recently approved in the EU and US for adults aged 60 years and older

- PMLiVE

AstraZeneca and Quell announce autoimmune disease partnership worth over $2bn

The collaboration will initially focus on developing cell therapies for type 1 diabetes and IBD

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links